Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Journal of Personalized Medicine
|
December 24, 2021
Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators
Danya Muilwijk, Marlou Bierlaagh, Peter van Mourik, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
November 29, 2020
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation
Gitte Berkers, Renske van der Meer, Harry Heijerman, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 11, 2025
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial
Isabelle Durieu, Barry Clements, Benedetta Fabrizzi, et al.
Journal of Medical Internet Research
|
January 9, 2025
The Long-Term Uptake of Home Spirometry in Regular Cystic Fibrosis Care: Retrospective Multicenter Observational Study
Pia Bertram, Martinus C Oppelaar, Michiel Age Bannier, et al.
Frontiers in Digital Health
|
November 8, 2024
Remote monitoring and teleconsultations can reduce greenhouse gas emissions while maintaining quality of care in cystic fibrosis
Martinus C Oppelaar, Michiel A G E Bannier, Monique H E Reijers, et al.
Journal of Medical Internet Research
|
December 3, 2024
Accuracy, Reproducibility, and Responsiveness to Treatment of Home Spirometry in Cystic Fibrosis: Multicenter, Retrospective, Observational Study
Martinus C Oppelaar, Hanneke Ac van Helvoort, Michiel Age Bannier, et al.
JHLT Open
|
March 27, 2025
Evaluation of Elexacafor/Tezacaftor/Ivacaftor therapy after lung transplantation in Cystic Fibrosis: The Dutch National KOALA study
, Johanna P van Gemert, Bart Luijk, et al.
Journal of Personalized Medicine
|
April 30, 2021
Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation
Maartje I Kristensen, Karin M de Winter-de Groot, Gitte Berkers, et al.
Journal of Medical Internet Research
|
August 6, 2024
Potential, Pitfalls, and Future Directions for Remote Monitoring of Chronic Respiratory Diseases: Multicenter Mixed Methods Study in Routine Cystic Fibrosis Care
Martinus C Oppelaar, Yvette Emond, Michiel A G E Bannier, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
June 6, 2020
Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation
Gitte Berkers, Renske van der Meer, Peter van Mourik, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Journal of Personalized Medicine
|
December 24, 2021
Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators
Danya Muilwijk, Marlou Bierlaagh, Peter van Mourik, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
November 29, 2020
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation
Gitte Berkers, Renske van der Meer, Harry Heijerman, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 11, 2025
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial
Isabelle Durieu, Barry Clements, Benedetta Fabrizzi, et al.
Journal of Medical Internet Research
|
January 9, 2025
The Long-Term Uptake of Home Spirometry in Regular Cystic Fibrosis Care: Retrospective Multicenter Observational Study
Pia Bertram, Martinus C Oppelaar, Michiel Age Bannier, et al.
Frontiers in Digital Health
|
November 8, 2024
Remote monitoring and teleconsultations can reduce greenhouse gas emissions while maintaining quality of care in cystic fibrosis
Martinus C Oppelaar, Michiel A G E Bannier, Monique H E Reijers, et al.
Journal of Medical Internet Research
|
December 3, 2024
Accuracy, Reproducibility, and Responsiveness to Treatment of Home Spirometry in Cystic Fibrosis: Multicenter, Retrospective, Observational Study
Martinus C Oppelaar, Hanneke Ac van Helvoort, Michiel Age Bannier, et al.
JHLT Open
|
March 27, 2025
Evaluation of Elexacafor/Tezacaftor/Ivacaftor therapy after lung transplantation in Cystic Fibrosis: The Dutch National KOALA study
, Johanna P van Gemert, Bart Luijk, et al.
Journal of Personalized Medicine
|
April 30, 2021
Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation
Maartje I Kristensen, Karin M de Winter-de Groot, Gitte Berkers, et al.
Journal of Medical Internet Research
|
August 6, 2024
Potential, Pitfalls, and Future Directions for Remote Monitoring of Chronic Respiratory Diseases: Multicenter Mixed Methods Study in Routine Cystic Fibrosis Care
Martinus C Oppelaar, Yvette Emond, Michiel A G E Bannier, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
June 6, 2020
Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation
Gitte Berkers, Renske van der Meer, Peter van Mourik, et al.
Page
of 3